Gynecology, gynecologic oncology, cardiology and rare diseases are areas where there will be changes regarding treatment as a result of the new list of reimbursed drugs coming into effect. Patients have gained access to reimbursement for 7 therapies in oncology indications and 26 non-oncology indications. 8 of these are for rare diseases.
What changes does the new reimbursement list bring? We have a list of
Published March 15, 2024 10:31
Fot. Getty Images/iStockphoto
In terms of rare diseases, there will be:
- Revising the provisions of the SMA drug program for Zolgensma gene therapy,
- Expanding access to RSV vaccine,
for sick children:
- On SMA until the age of 2,
- For cystic fibrosis up to 1 year of age.
- Comprehensive approach to the treatment of myasthenia gravis - inclusion in reimbursement of efgartigimod alfa, rituximab, mycophenolate mofetil,
- Coverage of olipudase alfa for the treatment of patients with acid sphingomyelinase deficiency - a highly innovative technology (TLI) funded
from the Medical Fund.
For women in gynecologic oncology and gynecology, reimbursement includes:
- pembrolizumab in the treatment of cervical cancer patients,
- relugolix, estradiol and norethisterone in the treatment of patients with uterine myomas,
- Expanding the indications for olaparib in the treatment of patients with recurrent ovarian, fallopian tube or primary peritoneal cancer without mutations in the BRCA 1/2 genes.
Cardiology, on the other hand, will follow:
- Expanding the reimbursement indications for ezetimibe, ezetimibe in combination with atorvastatin for the treatment of patients with heart failure,
- A change in the drug program to include treatment of pediatric patients and expanded indications for adults with lipid disorders,
- Expanding cardiovascular indications for empagliflozin in patients
with heart failure.
A detailed list of changes is included in the summary of the draft reimbursement notice
